Printer Friendly

Lupin Pharmaceuticals.

BALTIMORE -- Lupin Pharmaceuticals Inc. is dedicated to delivering high-quality, branded and generic pharmaceutical products trusted by health care professionals and patients across the United States.

Lupin is currently the fifth-largest generic pharmaceutical company in the U.S. by prescriptions dispensed, with 5.5% generic market share, according to IMS Health.

Lupin's journey began in 2003 with three Baltimore-based employees and Lupin's first U.S. generic product approval. As a market share leader in 44 generic products and among the top three in 79 products in the U.S., Lupin now markets a total of 124 products, according to IMS Health.

Last fiscal year, Lupin generated over $887 million in net revenues, contributing 43% of the company's global revenues.

In March of this year, Lupin completed its acquisition of privately held U.S.-based Gavis Pharmaceuticals LLC and Novel Laboratories Inc. Novel has since been renamed Lupin Somerset. The Gavis-Novel acquisition positions Lupin as having the fifth-largest pipeline of ANDA (Abbreviated New Drug Application) filings with the Food and Drug Administration. Lupin notes that it has brought significant, high-quality, affordable medications to the marketplace, which has helped fuel the growth of the company's business.

Today, Lupin has 45 first-to-file products, which include 25 exclusive FTF opportunities.

The momentum of Lupin's sustained growth year over year is a result of a valuable pipeline, solid customer relationships and smooth execution. Lupin has 163 ANDAs pending FDA approval and a deep pipeline of products under development for the U.S.

Lupin has a strong corporate culture of excellence in place, ensuring strict adherence to FDA regulations year after year.

Last fiscal year, Lupin launched 21 new products, including the successful commercialization of the exclusive generic equivalent of Glumetza. The majority of Lupin's products are vertically integrated, which ensures quality control throughout each step of product development and manufacturing. This gives Lupin an unparalleled advantage over its competitors, the company points out, as it is able to control its supply chain while offering competitive pricing.

Recent generic launches include diclofenac topical solution, 1.5% (Pennsaid 1.5%); norgestimate and ethinyl estradiol tablets (Ortho Tri-Cyclen); Blisovi Fe 1.5/30 tablets (Loestrin Fe 1.5/30); Blisovi Fe 1/20 tablets (Loestrin Fe 1/20); and zolpidem tartrate sublingual, CIV tablets (Intermezzo).

Lupin aims to continue to strengthen its market presence by launching new products and expanding its pipeline to offer medications in such new therapeutic areas as dermatology, pediatrics, women's health, inhalation and complex injectables.

Lupin says its steadfast commitment to quality and reliability has resulted in the company consistently delivering high-quality products, and its ongoing investment in technological capabilities will position the company to ensure customer satisfaction for years to come.

111 South Calvert St.

24th Floor

Baltimore, Md. 21202

Key contact: BOB HOFFMAN

Executive Vice President, U.S. Generics

Phone: (410) 576-2000

Diclofenac Topical Solution 1.5%           Pennsaid 1.5%
Norgestimate/Ethinyl Estradiol Tablets     Ortho Tri-Cyclen
Blisovi Fe 1.5/30 Tablets                  Loestrin Fe 1.5/30
Blisovi Fe 1/20 Tablets                    Loestrin Fe 1/20
Zolpidem Tartrate Sublingual CIV Tablets   Intermezzo
COPYRIGHT 2016 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Generic Drugs Report: Company Profiles
Publication:Chain Drug Review
Geographic Code:1U5MD
Date:Sep 26, 2016
Previous Article:Glenmark Pharmaceuticals.
Next Article:Carlsbad Tech.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters